ISSN 1016-5169 | E-ISSN 1308-4488
The Clinical Outcomes of COVID-19 in Patients on Warfarin: A Propensity Score Matching Study [Turk Kardiyol Dern Ars]
Turk Kardiyol Dern Ars. 2022; 50(8): 576-582 | DOI: 10.5543/tkda.2022.22344

The Clinical Outcomes of COVID-19 in Patients on Warfarin: A Propensity Score Matching Study

Mustafa Oğuz1, Tayyar Akbulut1, Faysal Saylık1, Abdulcabbar Sipar1, Murat Demirci2, Emrah Erdal1
1Department of Cardiology, Sultan Abdülhamid Han Training and Research Hospital, İstanbul, Turkey
2Department of Cardiology, Siirt Training and Research Hospital, University of Heath Science, Siirt, Turkey

COVID-19 is associated with vascular thrombosis in critical patients. However, warfarin has not been adequately studied in patients with COVID-19. This study aimed to evaluate whether the use of warfarin, a potent oral anticoagulant, was of clinical benefit in patients with COVID-19.

This was a retrospective cohort study of COVID-19 patients diagnosed at 3 different centers in Turkey between April 2020 and April 2021. Patients were grouped by whether they were taking warfarin or not. Propensity score matching analysis was used to compare the dif-ferences between the groups in mortality, hospitalization, and admission to the intensive care unit.

A propensity score analysis was performed on 128 patients in the warfarin group and 372 patients in the control group. After matching, 84 pairs of patients were compared. The patients in the control group were more likely to be admitted to the intensive care unit
(33.3% vs. 14.3%, respectively; P =.007) and had longer hospital stays than the warfarin group (7.1 vs. 14.1 days; P =.005). The warfarin group had a lower death rate compared to the control group (7.1% vs. 27.4%, respectively; P =.001), and surviving patients were significantly more likely to be in the warfarin group than the control group (56.1% vs. 20.7%,
respectively; P =.001). In patients on warfarin, there was a lower incidence of in-hospital death (log-rank test P =.005).

Warfarin therapy could provide clinical benefits in patients with COVID-19. The current data highlight the importance of potent anticoagulation in the treatment of COVID-19.

Keywords: Clinical benefi, ts, COVID-19, warfarin

How to cite this article
Mustafa Oğuz, Tayyar Akbulut, Faysal Saylık, Abdulcabbar Sipar, Murat Demirci, Emrah Erdal. The Clinical Outcomes of COVID-19 in Patients on Warfarin: A Propensity Score Matching Study. Turk Kardiyol Dern Ars. 2022; 50(8): 576-582

Corresponding Author: Mustafa Oğuz, Türkiye
Manuscript Language: English

Journal Metrics

Journal Citation Indicator: 0.18
CiteScore: 1.1
Source Normalized Impact
per Paper:
SCImago Journal Rank: 0.348

Quick Search

Copyright © 2023 Archives of the Turkish Society of Cardiology